Cubist Systematic Strategies LLC lowered its position in shares of Humana Inc (NYSE:HUM) by 50.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,412 shares of the insurance provider’s stock after selling 2,465 shares during the period. Cubist Systematic Strategies LLC’s holdings in Humana were worth $648,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. CCM Investment Advisers LLC increased its stake in shares of Humana by 0.5% during the first quarter. CCM Investment Advisers LLC now owns 39,289 shares of the insurance provider’s stock worth $10,562,000 after purchasing an additional 210 shares during the period. AMF Pensionsforsakring AB increased its stake in shares of Humana by 1.1% during the first quarter. AMF Pensionsforsakring AB now owns 27,680 shares of the insurance provider’s stock worth $7,441,000 after purchasing an additional 290 shares during the period. Brinker Capital Inc. increased its stake in shares of Humana by 16.7% during the first quarter. Brinker Capital Inc. now owns 2,377 shares of the insurance provider’s stock worth $640,000 after purchasing an additional 341 shares during the period. Stratos Wealth Partners LTD. increased its stake in shares of Humana by 448.7% during the first quarter. Stratos Wealth Partners LTD. now owns 417 shares of the insurance provider’s stock worth $112,000 after purchasing an additional 341 shares during the period. Finally, Synovus Financial Corp bought a new position in shares of Humana during the first quarter worth approximately $100,000. Institutional investors own 93.34% of the company’s stock.
HUM has been the topic of a number of recent research reports. ValuEngine upgraded Humana from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Argus increased their target price on Humana from $270.00 to $330.00 and gave the stock a “buy” rating in a research note on Monday, April 16th. Citigroup reiterated a “buy” rating and set a $340.00 target price (up previously from $280.00) on shares of Humana in a research note on Friday, June 1st. Zacks Investment Research lowered Humana from a “buy” rating to a “hold” rating in a research note on Friday, May 25th. Finally, Oppenheimer increased their target price on Humana from $305.00 to $311.00 and gave the stock an “outperform” rating in a research note on Thursday, May 3rd. Eight analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $286.83.
In other Humana news, CEO Bruce D. Broussard sold 17,604 shares of the firm’s stock in a transaction on Thursday, May 3rd. The stock was sold at an average price of $286.17, for a total value of $5,037,736.68. Following the sale, the chief executive officer now owns 89,259 shares of the company’s stock, valued at approximately $25,543,248.03. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jody L. Bilney sold 27,461 shares of the firm’s stock in a transaction on Friday, June 15th. The shares were sold at an average price of $306.46, for a total value of $8,415,698.06. Following the completion of the sale, the insider now directly owns 11,467 shares in the company, valued at approximately $3,514,176.82. The disclosure for this sale can be found here. In the last ninety days, insiders sold 124,009 shares of company stock worth $36,887,143. Company insiders own 0.60% of the company’s stock.
Shares of NYSE:HUM opened at $296.79 on Wednesday. The company has a market cap of $41.30 billion, a P/E ratio of 25.35, a P/E/G ratio of 1.56 and a beta of 0.92. Humana Inc has a 1 year low of $229.84 and a 1 year high of $309.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.55 and a current ratio of 1.55.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, May 2nd. The insurance provider reported $3.36 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.21 by $0.15. The business had revenue of $14.28 billion for the quarter, compared to the consensus estimate of $14.22 billion. Humana had a return on equity of 16.74% and a net margin of 3.36%. During the same quarter in the prior year, the business posted $2.75 earnings per share. analysts anticipate that Humana Inc will post 13.99 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, July 27th. Shareholders of record on Friday, June 29th will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date is Thursday, June 28th. Humana’s dividend payout ratio is presently 17.08%.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.